AMYT - Amryt Pharma plc Stock Price and Quote

AMYT [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Ireland

Index	-	P/E	-	EPS (ttm)	-0.09	Insider Own	0.08%	Shs Outstand	64.05M	Perf Week	0.07%
Market Cap	619.53M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	0.00%	Shs Float	29.82M	Perf Month	-0.34%
Income	-0.80M	PEG	-	EPS next Q	-0.04	Inst Own	75.80%	Short Float / Ratio	0.41% / 0.16	Perf Quarter	99.73%
Sales	243.60M	P/S	2.54	EPS this Y	100.50%	Inst Trans	0.65%	Short Interest	0.12M	Perf Half Y	104.78%
Book/sh	5.06	P/B	2.88	EPS next Y	75.00%	ROA	-0.10%	Target Price	17.50	Perf Year	82.00%
Cash/sh	1.96	P/C	7.44	EPS next 5Y	-	ROE	-0.20%	52W Range	6.41 - 14.77	Perf YTD	99.45%
Dividend	-	P/FCF	5.81	EPS past 5Y	15.10%	ROI	-5.50%	52W High	-1.42%	Beta	-
Dividend %	-	Quick Ratio	0.90	Sales past 5Y	-	Gross Margin	47.90%	52W Low	127.15%	ATR	0.06
Employees	241	Current Ratio	1.60	Sales Q/Q	8.10%	Oper. Margin	-19.80%	RSI (14)	59.59	Volatility	0.24% 0.30%
Optionable	Yes	Debt/Eq	0.66	EPS Q/Q	0.20%	Profit Margin	-0.30%	Rel Volume	0.00	Prev Close	14.56
Shortable	Yes	LT Debt/Eq	0.65	Earnings	-	Payout	0.00%	Avg Volume	736.87K	Price	14.56
Recom	2.70	SMA20	-0.14%	SMA50	-0.32%	SMA200	55.83%	Volume	0	Change	0.00%

Sep-06-22

Resumed

Canaccord Genuity

Buy

$19

Aug-19-21

Initiated

SVB Leerink

Outperform

$22

Aug-19-21

Initiated

Cowen

Outperform

$22

Jul-27-21

Initiated

H.C. Wainwright

Buy

$29

Mar-22-23 11:00AM	Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici GlobeNewswire
Feb-16-23 07:00AM	AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 GlobeNewswire
Jan-08-23 03:00PM	Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc GlobeNewswire
Jan-05-23 07:00AM	Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH GlobeNewswire
Dec-19-22 07:00AM	COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors GlobeNewswire
07:00AM	Loading…
Dec-05-22 07:00AM	European Commission approves Mycapssa® for the treatment of Acromegaly GlobeNewswire
Nov-30-22 07:00AM	Amryt Announces New Patent for Mycapssa® GlobeNewswire
Nov-03-22 07:00AM	Amryt Reports Q3 2022 Financial and Operational Results GlobeNewswire
Oct-31-22 07:00AM	Amryt Supports Acromegaly Awareness Day 2022 GlobeNewswire
Oct-25-22 07:00AM	The British Journal of Dermatology Publishes Results from Amryts EASE Phase 3 Trial in Epidermolysis Bullosa GlobeNewswire
Oct-24-22 07:00AM	Amryt Supports Global EB Awareness Week 2022 GlobeNewswire
Oct-19-22 07:00AM	Amryt to Report Q3 2022 Results on November 3, 2022 GlobeNewswire
Oct-18-22 07:00AM	COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly GlobeNewswire
Oct-17-22 07:00AM	Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) GlobeNewswire
Sep-23-22 07:00AM	Amryt Supports FH Awareness Day September 24, 2022 GlobeNewswire
07:30AM	Loading…
Sep-16-22 07:30AM	CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly GlobeNewswire
Sep-13-22 07:00AM	Amryt Announces New Patent for Mycapssa® GlobeNewswire
Sep-08-22 07:00AM	Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain GlobeNewswire
Sep-07-22 07:00AM	Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 GlobeNewswire
Aug-04-22 07:00AM	Amryt Reports Record Q2 2022 Results GlobeNewswire
Jul-21-22 07:00AM	Amryt to Report Q2 2022 Results on August 4, 2022 GlobeNewswire
Jul-14-22 07:00AM	Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome GlobeNewswire
Jul-07-22 07:00AM	Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 GlobeNewswire
Jul-01-22 07:00AM	Results of Annual General Meeting GlobeNewswire
Jun-27-22 07:00AM	Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer GlobeNewswire
Jun-24-22 07:00AM	Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA GlobeNewswire
Jun-23-22 07:00AM	European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB GlobeNewswire +7.45%
Jun-13-22 08:00AM	Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 GlobeNewswire -6.57%
Jun-08-22 07:00AM	Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 GlobeNewswire
Jun-01-22 07:00AM	Posting of Annual Report and Notice of AGM GlobeNewswire
07:00AM	Loading…
May-17-22 07:00AM	Amryt Announces Details of EMA Contingent Value Rights Payment GlobeNewswire
May-11-22 07:00AM	Amryt Announces New Patent for Mycapssa® GlobeNewswire
May-04-22 07:00AM	Amryt Reports Record Q1 2022 Results GlobeNewswire
Apr-22-22 10:15AM	CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB GlobeNewswire +14.60%
Apr-14-22 07:00AM	Amryt to Report Q1 2022 Results on May 4, 2022 GlobeNewswire
Apr-13-22 07:00AM	Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients GlobeNewswire
Mar-31-22 07:00AM	Amryt Supports World Lipodystrophy Day - March 31, 2022 GlobeNewswire
Mar-26-22 11:00AM	Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB GlobeNewswire
Mar-08-22 07:00AM	Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules) GlobeNewswire
Mar-03-22 09:18AM	Why Amryt Pharma (AMYT) Might Surprise This Earnings Season Zacks
07:00AM	Results of General Meeting GlobeNewswire
Mar-02-22 03:00PM	Amryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Feb-28-22 09:15AM	Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA GlobeNewswire -14.15%
Feb-25-22 07:00AM	Amryt Supports Rare Disease Day 2022 GlobeNewswire
Feb-23-22 07:00AM	Amryt to Report FY and Q4 2021 Results on March 9, 2022 GlobeNewswire -5.11%
Feb-22-22 07:00AM	Amryt Completes $125 Million Non-Dilutive Debt Refinancing GlobeNewswire
Feb-01-22 07:00AM	Notice of General Meeting GlobeNewswire
Jan-28-22 07:00AM	Amryt Announces Oleogel-S10 EMA Regulatory Update GlobeNewswire -5.55%
Jan-18-22 07:37AM	Amryt Pharma PLC Sponsored ADR (AMYT) Surges 5.5%: Is This an Indication of Further Gains? Zacks -5.88%
07:00AM	Amryt Announces New Patents for Oleogel-S10 GlobeNewswire
Jan-11-22 07:00AM	Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide GlobeNewswire
Jan-06-22 02:00AM	Key Dates for AIM Delisting GlobeNewswire
Jan-04-22 07:00AM	The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients GlobeNewswire
02:00AM	Total Voting Rights GlobeNewswire
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Dec-11-21 11:59AM	Timothy P. Lynchs Stonepine Capital Portfolio: Top 10 Healthcare Stocks Insider Monkey
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Dec-01-21 02:00AM	Total Voting Rights GlobeNewswire
Nov-30-21 02:00AM	Director/PDMR Shareholding GlobeNewswire
Nov-24-21 10:31AM	Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension Zacks
Nov-23-21 07:00AM	Amryt Provides Update on Regulatory Review Process for Oleogel-S10 GlobeNewswire -10.40%
Nov-22-21 02:00AM	Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM GlobeNewswire
Nov-03-21 08:35AM	Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Amryt Reports Strong Q3 2021 Results GlobeNewswire
Nov-01-21 09:00AM	Total Voting Rights GlobeNewswire
Oct-28-21 03:06PM	Earnings Preview: Amryt Pharma PLC Sponsored ADR (AMYT) Q3 Earnings Expected to Decline Zacks
Oct-20-21 07:00AM	Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3 GlobeNewswire
Oct-19-21 07:00AM	Amryt Announces New Patents for Oleogel-S10 and Mycapssa® GlobeNewswire
Oct-14-21 06:57AM	10 Pharmaceutical Stocks to Buy According to Timothy Lynchs Stonepine Capital Insider Monkey
Oct-01-21 02:00AM	Total Voting Rights GlobeNewswire
Sep-27-21 11:55AM	10 Cheap Pharmaceutical Stocks to Watch Insider Monkey
Sep-13-21 07:00AM	Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M GlobeNewswire
Sep-01-21 02:00AM	Total Voting Rights GlobeNewswire
Aug-19-21 02:00AM	Amryt Issues Ordinary Shares and Total Voting Rights GlobeNewswire -5.46%
Aug-10-21 09:20AM	Director/PDMR Shareholding GlobeNewswire
Aug-09-21 07:00AM	Amryt Virtual Capital Markets Event - September 13, 2021 1000-1200 EDT GlobeNewswire
Aug-06-21 07:00AM	Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance GlobeNewswire
Aug-05-21 10:50AM	Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights GlobeNewswire -5.50%
Jul-28-21 10:00AM	Result of General Meetings GlobeNewswire
Jul-12-21 07:00AM	Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6 GlobeNewswire
Jun-28-21 07:00AM	Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings GlobeNewswire -5.32%
Jun-15-21 06:45AM	Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. GlobeNewswire
Jun-10-21 09:32AM	10 Best Stocks to Buy According to Highbridge Capital Insider Monkey
Jun-07-21 07:00AM	FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting GlobeNewswire
Jun-04-21 09:35AM	Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review Zacks
Jun-03-21 08:07AM	Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder Benzinga
02:00AM	FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa GlobeNewswire
Jun-02-21 08:30AM	Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa GlobeNewswire
May-06-21 03:54PM	CHIASMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CHMA and Encourages Investors to Contact the Firm GlobeNewswire
11:47AM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Chiasma, Inc. Merger GlobeNewswire
08:04AM	Chiasma To Merge With Amryt SmarterAnalyst
May-05-21 05:36PM	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc. PR Newswire -10.44%
05:30PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Chiasma, Inc. PR Newswire
07:52AM	Chiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal Benzinga
07:05AM	Amryt Reports Record Q1 2021 Financial and Operating Results GlobeNewswire
07:00AM	Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases GlobeNewswire
06:45AM	Amryt Pharma Plc - ADR to Host Earnings Call ACCESSWIRE
Apr-17-21 09:20AM	10 Cheap Pharmaceutical Stocks For 2021 Insider Monkey
Apr-15-21 07:00AM	Amryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5 GlobeNewswire

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience